Poolbeg Pharma' CEO Jeremy Skillington joins Katie Pilbeam to talk about its interim results for the six months to 30th June 2022.
Skillington takes viewers through the highlights which include a strong cash balance of £18.9m, significant progress made on developing POLB 001, a treatment for severe influenza and its LPS human challenge trial commenced in July 2022 with initial results expected by year end 2022.
The company continues to explore further diseases treatments beyond severe influenza.